CAR-T Cell Therapy Market is estimated to be US$ 8.7 billion by 2034; Growing Prevalence of Cancer Disease to Foster Market Growth

CAR-T Cell Therapy is a way to get a type of white blood cells i.e., T cells to fight against cancer disease by changing them in laboratory to find and destroy cancer cells. In this therapy T cells are taken from patient blood and then changed in lab by adding chimeric antigen receptor (CAR) to specific cancer cell antigen.Growing prevalence of multiple myeloma cancer and rising incidence of leukemia and lymphoma disease has provided lucrative opportunities in target market growth. Growing adoption of CAR-T cell therapy product has further anticipated to increase the demand for CAR-T Cell Therapy market growth.CAR-T Cell Therapy Market was valued at US$ 2.7 Billion in 2024 and is projected to grow at a CAGR of 1.80% to reach US$ 8.7 Billion by 2034.

The report “CAR-T Cell Therapy Market, By Drug Type (Ciloleucel, Axicabtagene, Brexucabtagene Autoleucel, Tisagenlecleucel, and Others), By Indication (Acute Lymphocyctic Leukemia, Lymphoma, Non-Hodgkin Leukemia and Others), By End-Users (Hospitals, Cancer Research Centers, and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2034”

 Key Highlights:

• In May 2022, Novartis CART-T cell therapy tisagenlecleucel “Kymriah” approved by U.S. FDA (Food and Drug Administration) for use in adult patients with refractory or relapsed follicular lymphoma after systematic therapy.

• In March 2021, U.S. FDA (Food and Drug Administration) approved idecabtagene vicleucel (Abecma), a cell-based gene therapy in treating adult patients with multiple myeloma cancer disease. “Abecma” have become first cell-based gene therapy approved by FDA in treating multiple myeloma.

Analyst View:

CAR-T Cell Therapies has become standard treatment for patients with aggressive lymphomas. Ongoing research and development activities in CAR-T Cell Therapy is expected to provide lucrative opportunities in CAR-T Cell Therapy market growth in coming years. As a result, market competition is intensifying, and both big international corporations and start-ups are vying to establish position in the market.

Browse 60 market data tables* and 35 figures* through 140 slides and in-depth TOC on “CAR-T Cell Therapy Market, By Drug Type (Ciloleucel, Axicabtagene, Brexucabtagene Autoleucel, Tisagenlecleucel, and Others), By Indication (Acute Lymphocyctic Leukemia, Lymphoma, Non-Hodgkin Leukemia and Others), By End-Users (Hospitals, Cancer Research Centers, and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2034”

Key Market Insights from the report:

CAR-T Cell Therapy Market accounted for US$ 2.7 billion in 2024 and is estimated to be US$ 8.7 billion by 2034 and is anticipated to register a CAGR of 1.80%. The CAR-T Cell Therapy Market is segmented based on Drug Type, Indication, End-Users and Region.

• Based on Drug Type, CAR-T Cell Therapy Market is segmented into Ciloleucel, Axicabtagene, Brexucabtagene Autoleucel, Tisagenlecleucel, and Others.
• Based on Indication, CAR-T Cell Therapy Market is segmented into Acute Lymphocyctic Leukemia, Lymphoma, Non-Hodgkin Leukemia and Others.
• Based on End-Users, CAR-T Cell Therapy Market is segmented into Hospitals, Cancer Research Centers, and Others.
• By Region, the CAR-T Cell Therapy Market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East & Africa.

Competitive Landscape & their strategies of CAR-T Cell Therapy Market:

The prominent players operating in the CAR-T Cell Therapy Market includes, Bristol Myer Squibb, Merck & Co. Inc., Pfizer Inc., Bluebird Bio-Inc., Novartis AG, Caribou Biosciences Inc., Celgene Corporation, Sorrento Therapeutics Inc., Miltenyi Biotech, Cartesian Therapeutics and others.

To know more

Contact Us:

Sales

Prophecy Market Insights

U.S: 1 860 531 2574

RoW: 91 7775049802

Email- sales@prophecymarketinsights.com

Website- www.prophecymarketinsights.com

Blog- www.prophecyjournals.com